Fast-growing Cart.com has named its new chief people officer. Photo courtesy of Cart.com

Houston-based e-commerce software and services company Cart.com has hired a former Shopify executive as its chief people officer.

Before joining Cart.com, Lani Doyle was chief HR officer at Strategic Solutions Group, a provider of health care software. Previously, she was vice president of HR and people operations at 6 River Systems, a provider of software and robotics for warehouses. Prior to that, Doyle was head of talent development and operations at Shopify, an e-commerce platform for businesses that posted revenue of $7.1 billion in 2023.

Cart.com is one of the fastest-growing companies in commerce today, and I’m excited to partner with our teams to help drive growth and scalability,” Doyle says in a news release. “I am eager to contribute to shaping our culture and developing programming that supports and elevates high-performing teams, ensuring we achieve our ambitious goals.”

Omair Tariq, founder and CEO of Cart.com, describes Doyle as a “strategic leader” who will help develop the startup’s continually growing team. The company, founded in 2020 in Houston, employs more than 1,600 people.

“Her deep expertise in HR strategy and talent development will be instrumental as we accelerate our growth trajectory and foster a dynamic workplace culture,” says Frank Parker, chief operating officer of Cart.com.

In February, Cart.com made another high-level executive move by promoting Joe Barth from senior vice president of fulfillment to chief logistics officer.

Cart.com has more than 6,000 customers. The company handles more than 75 million orders per year from 14 fulfillment centers in the U.S.

Earlier this year, Tariq joined the Houston Innovators Podcast to share a bit about his company's growth and its relocation from Austin back to Houston.

"I think Austin served its purpose. It certainly allowed us to be in the limelight in all the right ways, and I'm grateful for it," Tariq says on the show. "But once we got to a point, once we closed our series C round and became a unicorn ... I think we're now at a scale where the infrastructure that Houston provides is probably something that will be more attractive and useful for us in the long term."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.